Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma.

Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB.

Clin Cancer Res. 2018 Aug 6. doi: 10.1158/1078-0432.CCR-17-3668. [Epub ahead of print]

PMID:
30082477
2.

The role of imaging in the clinical practice of radiation oncology for pancreatic cancer.

Koay EJ, Hall W, Park PC, Erickson B, Herman JM.

Abdom Radiol (NY). 2018 Feb;43(2):393-403. doi: 10.1007/s00261-017-1373-3.

PMID:
29110053
3.

Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores.

Patel PG, Selvarajah S, Guérard KP, Bartlett JMS, Lapointe J, Berman DM, Okello JBA, Park PC.

PLoS One. 2017 Jun 22;12(6):e0179732. doi: 10.1371/journal.pone.0179732. eCollection 2017.

4.

Preparation of Formalin-fixed Paraffin-embedded Tissue Cores for both RNA and DNA Extraction.

Patel PG, Selvarajah S, Boursalie S, How NE, Ejdelman J, Guerard KP, Bartlett JM, Lapointe J, Park PC, Okello JB, Berman DM.

J Vis Exp. 2016 Aug 21;(114). doi: 10.3791/54299.

5.

Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes.

Georgescu I, Gooding RJ, Doiron RC, Day A, Selvarajah S, Davidson C, Berman DM, Park PC.

Cancer Metab. 2016 May 5;4:8. doi: 10.1186/s40170-016-0149-5. eCollection 2016.

6.

Perturbation of water-equivalent thickness as a surrogate for respiratory motion in proton therapy.

Matney JE, Park PC, Li H, Court LE, Zhu XR, Dong L, Liu W, Mohan R.

J Appl Clin Med Phys. 2016 Mar 8;17(2):368-378. doi: 10.1120/jacmp.v17i2.5795.

7.

Motion-robust intensity-modulated proton therapy for distal esophageal cancer.

Yu J, Zhang X, Liao L, Li H, Zhu R, Park PC, Sahoo N, Gillin M, Li Y, Chang JY, Komaki R, Lin SH.

Med Phys. 2016 Mar;43(3):1111-8. doi: 10.1118/1.4940789.

PMID:
26936698
8.

MRI-based computed tomography metal artifact correction method for improving proton range calculation accuracy.

Park PC, Schreibmann E, Roper J, Elder E, Crocker I, Fox T, Zhu XR, Dong L, Dhabaan A.

Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):849-56. doi: 10.1016/j.ijrobp.2014.12.027.

PMID:
25752400
9.

Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers.

Liu W, Liao Z, Schild SE, Liu Z, Li H, Li Y, Park PC, Li X, Stoker J, Shen J, Keole S, Anand A, Fatyga M, Dong L, Sahoo N, Vora S, Wong W, Zhu XR, Bues M, Mohan R.

Pract Radiat Oncol. 2015 Mar-Apr;5(2):e77-86. doi: 10.1016/j.prro.2014.08.002. Epub 2014 Sep 11.

10.

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA.

BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.

11.

Effects of respiratory motion on passively scattered proton therapy versus intensity modulated photon therapy for stage III lung cancer: are proton plans more sensitive to breathing motion?

Matney J, Park PC, Bluett J, Chen YP, Liu W, Court LE, Liao Z, Li H, Mohan R.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):576-82. doi: 10.1016/j.ijrobp.2013.07.007.

12.

Statistical assessment of proton treatment plans under setup and range uncertainties.

Park PC, Cheung JP, Zhu XR, Lee AK, Sahoo N, Tucker SL, Liu W, Li H, Mohan R, Court LE, Dong L.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):1007-13. doi: 10.1016/j.ijrobp.2013.04.009. Epub 2013 May 18.

13.

A novel dose-based positioning method for CT image-guided proton therapy.

Cheung JP, Park PC, Court LE, Ronald Zhu X, Kudchadker RJ, Frank SJ, Dong L.

Med Phys. 2013 May;40(5):051714. doi: 10.1118/1.4801910.

14.

Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers.

Liu W, Frank SJ, Li X, Li Y, Park PC, Dong L, Ronald Zhu X, Mohan R.

Med Phys. 2013 May;40(5):051711. doi: 10.1118/1.4801899.

15.

Array comparative genomic hybridization in osteosarcoma.

Sadikovic B, Park PC, Selvarajah S, Zielenska M.

Methods Mol Biol. 2013;973:227-47. doi: 10.1007/978-1-62703-281-0_15. Review.

PMID:
23412794
16.

Comprehensive analysis of proton range uncertainties related to patient stopping-power-ratio estimation using the stoichiometric calibration.

Yang M, Zhu XR, Park PC, Titt U, Mohan R, Virshup G, Clayton JE, Dong L.

Phys Med Biol. 2012 Jul 7;57(13):4095-115. doi: 10.1088/0031-9155/57/13/4095. Epub 2012 Jun 7.

17.

Fast range-corrected proton dose approximation method using prior dose distribution.

Park PC, Cheung J, Zhu XR, Sahoo N, Court L, Dong L.

Phys Med Biol. 2012 Jun 7;57(11):3555-69. doi: 10.1088/0031-9155/57/11/3555. Epub 2012 May 16.

18.

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H.

BMC Cancer. 2012 Mar 19;12:91. doi: 10.1186/1471-2407-12-91.

19.

Prostate cancer as a model system for genetic diversity in tumors.

Squire JA, Park PC, Yoshimoto M, Alami J, Williams JL, Evans A, Joshua AM.

Adv Cancer Res. 2011;112:183-216. doi: 10.1016/B978-0-12-387688-1.00007-7. Review.

PMID:
21925305
20.

A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties.

Park PC, Zhu XR, Lee AK, Sahoo N, Melancon AD, Zhang L, Dong L.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e329-36. doi: 10.1016/j.ijrobp.2011.05.011. Epub 2011 Jun 22.

21.

Immunohistochemical Assessment of Expression of Centromere Protein-A (CENPA) in Human Invasive Breast Cancer.

Rajput AB, Hu N, Varma S, Chen CH, Ding K, Park PC, Chapman JA, Sengupta SK, Madarnas Y, Elliott BE, Feilotter HE.

Cancers (Basel). 2011 Dec 6;3(4):4212-27. doi: 10.3390/cancers3044212.

22.

Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH.

Selvarajah S, Yoshimoto M, Ludkovski O, Park PC, Bayani J, Thorner P, Maire G, Squire JA, Zielenska M.

Cytogenet Genome Res. 2008;122(1):5-15. doi: 10.1159/000151310. Epub 2008 Oct 14.

PMID:
18931480
23.

Inhibition of N-ethylmaleimide-sensitive factor protects against myocardial ischemia/reperfusion injury.

Calvert JW, Gundewar S, Yamakuchi M, Park PC, Baldwin WM 3rd, Lefer DJ, Lowenstein CJ.

Circ Res. 2007 Dec 7;101(12):1247-54. Epub 2007 Oct 11.

24.

Leydig cell origin of testicular carcinoid tumour: immunohistochemical and electron microscopic evidence.

Mai KT, Park PC, Yazdi HM, Carlier M.

Histopathology. 2006 Nov;49(5):548-9. No abstract available.

PMID:
17064307
25.

Predictive value of prostatic adenocarcinoma after a negative prostate biopsy.

Park PC, Mai KT, Roustan Delatour NL, Morash C, Cagiannos I.

BJU Int. 2006 Nov;98(5):986-8.

26.

The breakage-fusion-bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma.

Selvarajah S, Yoshimoto M, Park PC, Maire G, Paderova J, Bayani J, Lim G, Al-Romaih K, Squire JA, Zielenska M.

Chromosoma. 2006 Dec;115(6):459-67. Epub 2006 Aug 9.

PMID:
16897100
27.

Stem cell enrichment approaches.

Park PC, Selvarajah S, Bayani J, Zielenska M, Squire JA.

Semin Cancer Biol. 2007 Jun;17(3):257-64. Epub 2006 Apr 29. Review.

PMID:
16814562
28.

Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases.

Mai KT, Park PC, Yazdi HM, Saltel E, Erdogan S, Stinson WA, Cagiannos I, Morash C.

Eur Urol. 2006 Nov;50(5):1111-4. Epub 2006 Jan 18.

PMID:
16626859
29.

Transcriptional profiling of medulloblastoma in children.

Park PC, Taylor MD, Mainprize TG, Becker LE, Ho M, Dura WT, Squire J, Rutka JT.

J Neurosurg. 2003 Sep;99(3):534-41.

PMID:
12959442
30.

Chromosomal instability in osteosarcoma and its association with centrosome abnormalities.

Al-Romaih K, Bayani J, Vorobyova J, Karaskova J, Park PC, Zielenska M, Squire JA.

Cancer Genet Cytogenet. 2003 Jul 15;144(2):91-9.

PMID:
12850370
31.

Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma.

Vukovic B, Park PC, Al-Maghrabi J, Beheshti B, Sweet J, Evans A, Trachtenberg J, Squire J.

Oncogene. 2003 Apr 3;22(13):1978-87.

PMID:
12673203
32.

Microarray CGH.

Beheshti B, Park PC, Braude I, Squire JA.

Methods Mol Biol. 2002;204:191-207. No abstract available.

PMID:
12397799
35.

Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis.

Beheshti B, Park PC, Sweet JM, Trachtenberg J, Jewett MA, Squire JA.

Neoplasia. 2001 Jan-Feb;3(1):62-9.

36.

Association of DNAse sensitive chromatin domains with the nuclear periphery in 3T3 cells in vitro.

Chan JK, Park PC, De Boni U.

Biochem Cell Biol. 2000;78(2):67-78.

PMID:
10874467
38.

Dynamics of structure-function relationships in interphase nuclei.

Park PC, De Boni U.

Life Sci. 1999;64(19):1703-18. Review.

PMID:
10353624
39.

Total spinal anesthesia following epidural saline injection after prolonged epidural anesthesia.

Park PC, Berry PD, Larson MD.

Anesthesiology. 1998 Nov;89(5):1267-70. No abstract available.

PMID:
9822021
41.

Changes in morphology and spatial position of coiled bodies during NGF-induced neuronal differentiation of PC12 cells.

Janevski J, Park PC, De Boni U.

J Histochem Cytochem. 1997 Nov;45(11):1523-31.

PMID:
9358854
47.

Supplemental Content

Support Center